topical infliximab

DRUG3 trials

Sponsors

James Chodosh, MD, MPH, Centre hospitalier de l'Université de Montréal (CHUM)

Conditions

Glaucoma Following SurgeryMucous Membrane PemphigoidSterile Corneal MeltStevens-Johnson SyndromeToxic Epidermal Necrolysis (Lyell) Syndrome

Phase 1

Topical Infliximab in Autoimmune Eyes With Keratoprosthesis

WithdrawnNCT02126020

James Chodosh, MD, MPHMucous Membrane Pemphigoid, Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis (Lyell) Syndrome

Start: 2014-11-30End: 2017-04-03Updated: 2017-04-07

Topical Infliximab for Sterile Corneal Melt

CompletedNCT02987686

Centre hospitalier de l'Université de Montréal (CHUM)Sterile Corneal Melt

Start: 2017-09-06End: 2025-11-15Updated: 2026-04-28

Topical Infliximab in Eyes With Penetrating Keratoplasty

RecruitingNCT05180994

Centre hospitalier de l'Université de Montréal (CHUM)Glaucoma Following Surgery

Start: 2022-05-01End: 2028-03-01Target: 50Updated: 2026-04-27